AbbVie
ABBV stock analysis · Health Care · Biotechnology
As of · fund-implied per-share value
Fund holding value ÷ shares held. Not a live quote; not adjusted for later stock splits.
View SEC fund filing ↗Price × SEC outstanding shares. Shares measured 2026-04-28. Approximate; share and price dates can differ.
View share-count filing ↗DCF value
Equity cash-flow scenario · SEC outstanding shares at 2026-04-28 · -39.1% versus input cap
How this is calculated ↗Reverse DCF
Annual basis · read assumptions below
How this is calculated ↗Relative valuation
6 industry peers · median 21.5×
How this is calculated ↗Historical multiples
7 annual observations · snapshot P/E 106.2× · 102.2% versus history
How this is calculated ↗Free cash flow yield
Annual basis · read assumptions below
How this is calculated ↗ROIC / quality
Normalized tax · financing-capital proxy
How this is calculated ↗Value composite
Requires three valuation yields and at least five covered sector peers.
How this is calculated ↗12–1 price momentum
Split and corporate-action verification is incomplete for these fund observations. Verified adjusted endpoints are required for 12–1 momentum.
How this is calculated ↗Asset growth
Annual basis · read assumptions below
How this is calculated ↗Net payout yield
Annual basis · read assumptions below
How this is calculated ↗Accrual quality
Annual basis · read assumptions below
How this is calculated ↗Fundamental momentum
Annual basis · read assumptions below
How this is calculated ↗Follow the cash
ANNUAL · USDOperating cash flow and reinvestment over time
Annual USD. Negative bars use a compressed lower scale. Hover or inspect the financial history table for exact values.
Make the assumptions yours
How sensitive is the valuation?
| Return / Growth | 3.0% | 5.0% | 7.0% |
|---|---|---|---|
| 8.0% | $192.10 | $209.60 | $228.42 |
| 10.0% | $140.77 | $153.16 | $166.46 |
| 12.0% | $111.06 | $120.51 | $130.64 |
Annual financial history
Open SEC filings ↗| Fiscal year-end | Revenue | Net income | Operating cash flow | Capital expenditure | Assets |
|---|---|---|---|---|---|
| 2025-12-31 | 61.2B | 4.2B | 19B | 1.2B | 134B |
| 2024-12-31 | 56.3B | 4.3B | 18.8B | 974M | 135.2B |
| 2023-12-31 | 54.3B | 4.9B | 22.8B | 777M | 134.7B |
| 2022-12-31 | 58.1B | 11.8B | 24.9B | 695M | 138.8B |
| 2021-12-31 | 56.2B | 11.5B | 22.8B | 787M | 146.5B |
| 2020-12-31 | 45.8B | 4.6B | 17.6B | 798M | 150.6B |
| 2019-12-31 | 33.3B | 7.9B | 13.3B | 552M | 89.1B |
| 2018-12-31 | 32.8B | 5.7B | 13.4B | 638M | 59.4B |
USD, abbreviated. Restated annual history; not a point-in-time backtest. Missing values appear as dashes.
Trace the inputs
MODEL ANNUAL PERIOD| Input | Value | SEC tag / source | Filed |
|---|---|---|---|
| revenue | 61.2B | RevenueFromContractWithCustomerExcludingAssessedTax | 2026-02-20 |
| netIncome | 4.2B | ProfitLoss Explicit consolidated amount, including the portion attributable to noncontrolling interests. | 2026-02-20 |
| Parent/common earnings proxy | 4.2B | NetIncomeLossAvailableToCommonStockholdersBasic | 2026-02-20 |
| cfo | 19B | NetCashProvidedByUsedInOperatingActivities | 2026-02-20 |
| capex | 1.2B | PaymentsToAcquirePropertyPlantAndEquipment | 2026-02-20 |
| operatingIncome | 15.1B | OperatingIncomeLoss | 2026-02-20 |
| assets | 134B | Assets | 2026-02-20 |
| equity | -3.2B | StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Explicit consolidated amount, including the portion attributable to noncontrolling interests. | 2026-02-20 |
| Parent book equity proxy | -3.3B | StockholdersEquity | 2026-02-20 |
| debt | 64.5B | LongTermDebt | 2026-02-20 |
| shortDebt | 2.5B | ShortTermBorrowings | 2026-02-20 |
| cash | 5.2B | CashAndCashEquivalentsAtCarryingValue | 2026-02-20 |
| shares | 1.8B | WeightedAverageNumberOfDilutedSharesOutstanding | 2026-02-20 |
| dividends | 11.7B | PaymentsOfDividends | 2026-02-20 |
| buybacks | 980M | PaymentsForRepurchaseOfCommonStock | 2026-02-20 |
| issuance | 172M | Reviewed manual correction Bounded FY2025-12-31 consolidated financing-statement extraction. Proceeds from the exercise of stock options: 172000000 USD [us-gaap:ProceedsFromStockOptionsExercised]. All 11 financing lines reconcile exactly to reported financing cash flow -12724000000 USD. Cash inflows from common shares, employee plans and option exercises are summed once as displayed on the statement; noncash compensation, withholding payments, preferred and noncontrolling interests are excluded. This review applies only to this issuer and fiscal period. Source limitation: the statement also aggregates other financing cash flows (net 68000000 USD). Their common-equity portion is not separately disclosed here. Issuance is the sum of separately reported common cash-issuance lines, not an independently verified gross total; additional equity flows may be inside those aggregates. | 2026-02-20 |